NBSE

NeuBase Therapeutics, Inc. (NBSE) | Rumor.io

NeuBase Therapeutics

NBSE

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NBSE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Feb 26

The company NeuBase Therapeutics, Inc. (NBSE) has seen increased volume, with some traders expecting a potential breakout above $1.08.
Price targets for NBSE range from $2 to $6, with some traders expecting a strong upward trend.
Insider activity has been noted, with some traders speculating that insider buying may be contributing to the stock's recent 41% increase over the weekend.

Generated by AI

Sentiment

Of the messages about NBSE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	100% +26.09
Bearish	0%	0%	0%	0% -26.09

Bullish· Feb 26

$NBSE has the potential to reach $2-$3 per share.
$NBSE's small float and increasing volume could lead to a significant price increase.
$NBSE is expected to break out above $1.00, with some analysts predicting a target price of $1.50 and a potential high of $5-$6.

Bearish· Nov 30

The company's stock price is highly volatile and prone to sudden drops, making it difficult to hold onto.
The stock's low float and high cash reserves may be indicative of a strategic alternative or takeover, which could negatively impact the stock price.
The company's recent halts and lack of catalysts or PR/news may be indicative of an orchestrated pump and dump scheme, leading to a potential collapse in the stock price.

Generated by AI

Topics

Of the messages about NBSE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	100%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Announcements· Sep 6

Symetryx Corporation has acquired 20% of the issued and outstanding common stock in NeuBase Therapeutics, Inc. ($NBSE).
Symetryx is urging the Board to issue a special $1 per share dividend, citing NeuBase's cash balance of approximately $14.7 million.
NeuBase Therapeutics' shareholder base invested in the company for its therapeutic work, and Symetryx believes a special dividend and merger exploration could be a "win-win" for shareholders.

Technical Analysis· Sep 7

$NBSE is showing signs of bottoming out and has a low float, making it a potential buy.
The stock has a short squeeze setup, with 450K shares shorted and a potential bounce back to $2.
$NBSE is in an uptrend channel and has formed a head and shoulders pattern on the daily chart, indicating a potential retrace and accumulation.

Generated by AI

Community

Of the messages about NBSE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	60%
Newcomers	0%	0%	0%	40%

Regulars· Apr 22

NeuBase Therapeutics (NBSE) announced a proposed public offering of common stock, with plans to sell 8,000,000 shares at $5.00 per share, raising $40 million.
The company's stock has been declining, with a new 52-week low reached on the day the offering was announced, and has continued to slump in after-hours trading.
The proposed public offering has been priced, with NBSE stock prices rising 10.57% on the news, and the company has filed a Form 8-K with the SEC regarding the offering.

Newcomers· Sep 7

The price of $NBSE has increased significantly, with one user noting a 300% return and another user highlighting a "beautiful" daily chart.
Several users are taking advantage of the low float and high volume in $NBSE, noting that it is a good opportunity to buy and potentially profit from a "crazy, irrational bargain".
The company's stock buyback news is being seen as a catalyst for further price movement, with one user suggesting that the run could continue into Friday.

Generated by AI

Also Discussed

Investors talking about NBSE also mention

#	Name	Attention
1	AXLA - Axcella Health Inc.	——
2	NVOS - Novo Integrated Sciences, Inc.	——
3	EBET - EBET, Inc.	——
4	ICCT - iCoreConnect Inc.	——
5	ZVSA - ZyVersa Therapeutics, Inc.	——
6	Stoke Therapeutics, Inc.STOK	0%new
7	Avalo Therapeutics, Inc.AVTX	0%0
8	BioNexus Gene Lab Corp.BGLC	0%0
9	Imac Holdings Inc.BACK	0%new
10	Allarity Therapeutics Inc.ALLR	0%-0.01